

# IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES IN OLDER ADULTS AGED $\geq 50$ YEARS WITH HIV-1 AFTER SWITCHING TO A 2-DRUG REGIMEN OF FIXED-DOSE COMBINATION DTG/3TC: 48-WEEK RESULTS FROM THE SALSA STUDY

Kumar PN<sup>1</sup>, Hocqueloux L<sup>2</sup>, Jonsson-Oldenbüttel C<sup>3</sup>, García Deltoro M<sup>4</sup>, Clarke AE<sup>5</sup>, Di Giambenedetto S<sup>6</sup>, Lu P-L<sup>7</sup>, Brites C<sup>8</sup>, Oyee J<sup>9</sup>, Evitt LA<sup>10</sup>, Gordon LA<sup>11</sup>, Blair E<sup>11</sup>, Wynne B<sup>11</sup>, Okoli C<sup>10</sup>, van Wyk J<sup>10</sup>, Priest J<sup>11</sup>, Latorre L<sup>12</sup>

<sup>1</sup>Georgetown University Medical Center, Washington, DC, USA; <sup>2</sup>Centre Hospitalier Régional d'Orléans, Orléans, France; <sup>3</sup>MVZ München am Goetheplatz, Munich, Germany; <sup>4</sup>Consortium General University Hospital of Valencia, Valencia, Spain; <sup>5</sup>Royal Sussex County Hospital and Brighton & Sussex Medical School, Brighton, UK; <sup>6</sup>Fondazione Policlinico Universitario Agostino Gemelli IRCCS and Università Cattolica del Sacro Cuore, Rome, Italy; <sup>7</sup>Kaohsiung Medical University, Kaohsiung, Taiwan; <sup>8</sup>Universidade Federal da Bahia, Salvador, Brazil; <sup>9</sup>GlaxoSmithKline, Brentford, UK; <sup>10</sup>ViiV Healthcare, Brentford, UK; <sup>11</sup>ViiV Healthcare, Research Triangle Park, NC, USA; <sup>12</sup>Viiv Healthcare, Abbotsford, Australia.

**Background:** Older adults living with HIV (OALWH) have unmet needs beyond viral suppression, and patient-reported health outcomes provide insight into these needs. In the SALSA study (NCT04021290), switching to the 2-drug regimen dolutegravir/lamivudine (DTG/3TC) was non-inferior in maintaining virologic suppression at Week 48 compared with continuing 3-/4-drug (3/4DR) current antiretroviral regimen (CAR) in virologically suppressed adults, including OALWH. We present patient-reported health outcomes from SALSA by baseline age.

**Methods:** SALSA is a randomized, open-label study of virologically suppressed adults on stable 3/4DR who switched to DTG/3TC or continued CAR for 52 weeks. A post hoc analysis of treatment satisfaction (HIV Treatment Satisfaction Questionnaire, status version [HIVTSQs]) and symptom bother (symptom distress module [SDM]) by age ( $\geq 50$  and  $< 50$  years) was performed.

**Results:** Similar numbers of participants were aged  $\geq 50$  years (DTG/3TC, 98; CAR, 95) and  $< 50$  years (DTG/3TC, 148; CAR, 152) in each group. Participants aged  $\geq 50$  years who switched to DTG/3TC vs continued CAR had greater improvements in HIVTSQs total score and lifestyle/ease sub-score at Weeks 4 (adjusted difference, 1.6; 95% CI, 0.3-3.0) and 24 (1.3; 0.1-2.5), which were stable through Week 48; improvements were comparable in general satisfaction/clinical sub-score. Participants aged  $< 50$  years in the DTG/3TC group had improved HIVTSQs total score and sub-scores vs CAR at all time points assessed. Participants aged  $\geq 50$  years in the DTG/3TC group had numerical improvements in SDM score vs CAR at Week 4 (adjusted difference, -1.8; 95% CI, -3.6, 0.0), which remained stable through Week 48. Participants aged  $< 50$  years had comparable improvements in SDM between treatment groups.

**Conclusion:** Rapid and stable improved treatment satisfaction through 48 weeks was reported by OALWH who switched to DTG/3TC. Comparable results were observed among participants aged  $< 50$  years. These findings support improved patient outcomes among OALWH after switch to DTG/3TC vs continuing CAR.

**Disclosure of Interest Statement:** PNK participated in advisory boards/owns stock in J&J, ViiV Healthcare, Gilead, Theratechnologies, MSD, GlaxoSmithKline, and Pfizer. LH received support from ViiV Healthcare, MSD, and Gilead. CJ-O received support from ViiV Healthcare/GlaxoSmithKline, AbbVie, Gilead, Janssen, and RG. MGD received support from ViiV Healthcare, Janssen, Gilead, MSD, and AbbVie. AEC received support from GlaxoSmithKline, ViiV Healthcare, Gilead, and Janssen. SDG is a paid consultant/advisory board member for Gilead, ViiV Healthcare, Janssen-Cilag, MSD, and BMS. P-LL has no conflicts. CB received support/participated in advisory boards for GlaxoSmithKline, Gilead, and MSD. JO, LAE, LAG, EB, BW, CO, JvW, LL and JP are employees of GlaxoSmithKline or ViiV Healthcare and own stock in GlaxoSmithKline. This study was funded by ViiV Healthcare.